Investigating immune cell behavior in lupus nephritis
Official title: Project 2 - BWH
Funded at Beth Israel Deaconess Medical Center · NIH-11046589 · Data updated 2026-11-12
This study is looking at how immune cells move to the kidneys in people with lupus nephritis, which is a serious kidney issue caused by lupus, to find better ways to treat the condition.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $849,884 |
| NIH project number | 5P01AI179405-02 |
| Project ID | NIH-11046589 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus, particularly those who have developed lupus nephritis.
✕Less likely to help
Patients without a diagnosis of systemic lupus erythematosus or those who do not have lupus nephritis may not benefit from this research.
What this research studies
This research focuses on understanding how immune cells migrate to the kidneys in patients with lupus nephritis, a serious complication of systemic lupus erythematosus. By studying the role of specific signaling pathways and specialized blood vessels in the kidneys, the research aims to uncover mechanisms that drive inflammation and disease progression. Patients may benefit from insights gained through advanced experimental techniques that could lead to improved therapeutic strategies for managing lupus nephritis.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better control kidney inflammation in lupus nephritis patients.
How similar studies have gone: Previous research has shown promising results in understanding immune cell behavior in related conditions, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Abdi, Reza — Beth Israel Deaconess Medical Center
- Study coordinator: Abdi, Reza
Related research
Other NIH-funded projects on the same topics.
-
SATURN MRI ancillary study: statins after intracerebral hemorrhage and brain MRI markers
This study looks at what happens to brain MRI markers and health outcomes when people with a specific type of brain bleed continue or stop taking statins.
-
Statin use after brain bleed MRI study in ICH patients (SATURN MRI) Ancillary Study
This project tests whether continuing or stopping statin therapy after an intracerebral hemorrhage affects brain changes seen on MRI and related health outcomes in people with lobar ICH.
-
Statin use after brain bleed: SATURN MRI ancillary study
This project tests whether continuing statin medicines after a brain bleed (lobar intracerebral hemorrhage) affects new brain blood vessel findings and long-term health.
-
XenCAT: Single Cell Atlas for Xenopus
Aims to map gene activity at the single-cell level in Xenopus to help understand how cells develop and how this relates to human disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.